Changes in the Subchondral Bone, Visfatin, and Cartilage Biomarkers after Pharmacological Treatment of Experimental Osteoarthritis with Metformin and Alendronate
Authors:
- Sevdalina Nikolova LambovaSevdalina Nikolova Lambova
- Nina IvanovskaNINina Ivanovska
- Stela StoyanovaSSStela Stoyanova
- Lyudmila Belenska-TodorovaLBLyudmila Belenska-Todorova
- Elenka GeorgievaEGElenka Georgieva
- Tsvetelina BatsalovaTsvetelina Batsalova
- Dzhemal MotenDzhemal Moten
- Desislava ApostolovaDADesislava Apostolova
- Balik DzhambazovBalik Dzhambazov
Open Access
- 14 June 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (12) , 10103
Abstract
Subchondral bone that has intense communication with the articular cartilage might be a potential target for pharmacological treatment in the early stages of osteoarthritis (OA). Considering the emerging data about the role of adipokines in the pathogenesis of OA, the administration of drugs that influence their level is also intriguing. Metformin and alendronate were administered in mice with collagenase-induced OA (CIOA) as a monotherapy and in combination. Safranin O staining was used for the assessment of changes in subchondral bone and articular cartilage. Before and after treatment, serum levels of visfatin and biomarkers of cartilage turnover (CTX-II, MMP-13, and COMP) were assessed. In the current study, the combined administration of alendronate and metformin in mice with CIOA led to the protection against cartilage and subchondral bone damage. In mice with CIOA, metformin led to a decrease in visfatin level. In addition, treatment with metformin, alendronate, or their combination lowered the level of cartilage biomarkers (CTX-II and COMP), while the level of MMP-13 was not influenced. In conclusion, personalized combination treatment in OA according to clinical phenotype, especially in the early stages of the disease, might lead to the identification of a successful disease-modifying therapeutic protocol in OA.Keywords
Funding Information
- Bulgarian National Science Fund (KP-06-N33/9)
This publication has 64 references indexed in Scilit:
- CTX-II is a marker of cartilage degradation but not of bone turnoverOsteoarthritis and Cartilage, 2013
- Prevalent cartilage damage and cartilage loss over time are associated with incident bone marrow lesions in the tibiofemoral compartments: the MOST studyOsteoarthritis and Cartilage, 2013
- Bisphosphonates: The first 40yearsBone, 2011
- Pathophysiology of rheumatoid arthritisCurrent Opinion in Rheumatology, 2011
- Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritisClinical and Experimental Medicine, 2011
- Relationship between trabecular bone structure and articular cartilage morphology and relaxation times in early OA of the knee joint using parallel MRI at 3 TOsteoarthritis and Cartilage, 2008
- Pharmacokinetics of AlendronateClinical Pharmacokinetics, 1999
- Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.Journal of Clinical Investigation, 1996
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the kneeArthritis & Rheumatism, 1986
- Radiological Assessment of Osteo-ArthrosisAnnals of the Rheumatic Diseases, 1957